This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
by Zacks Equity Research
Expanding transplant logistic service business is likely to have driven TransMedics' third-quarter 2024 performance.
HSIC Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Henry Schein is expected to report impressive sales in both its businesses in the third quarter of 2024, along with a low pace of recovery from the cyber incident.
GEHC Stock Declines Despite the Unveiling of CareIntellect Application
by Zacks Equity Research
GE Healthcare announces CareIntellect for Oncology to provide multi-modal patient data from disparate systems into a single view using generative AI.
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
by Zacks Equity Research
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
iRhythm Technologies Stock Rises Post FDA Clearance for Zio AT
by Zacks Equity Research
IRTC receives FDA 510(k) clearance for prior design modifications to its Zio AT device, reinforcing its commitment to quality and compliance.
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
Boston Scientific Shares Likely to Gain After FARAWAVE NAV Approval
by Zacks Equity Research
BSX receives FDA approval for the FARAWAVE NAV Ablation Catheter and FARAVIEW Software, enhancing cardiac mapping and ablation workflows for AF treatment.
Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards?
by Zacks Equity Research
Within Spatial Biology, TECH is expected to have recorded strong growth, banking on the strong adoption of its new spatial biology instrument COMET.
STE Gears Up for Q2 Earnings: Here's What You Need to Know
by Zacks Equity Research
STERIS' second-quarter fiscal 2025 results are likely to reflect the positives of normalizing the Healthcare backlog.
Myriad Genetics Shares Fall Despite Partnership With jscreen
by Zacks Equity Research
MYGN partners with jscreen to expand access to high-quality hereditary cancer and reproductive genetics testing for high-risk populations.
BIO Gears Up for Q3 Earnings: Here's What You Need to Know
by Zacks Equity Research
Within Bio-Rad's Life Science business, the ongoing weakness in the biotech and biopharma end markets might have severely affected sales.
Aurora Cannabis Stock Rises Following Medical Cannabis Oil Launch
by Zacks Equity Research
ACB and MedReleaf Australia launch premium medical cannabis oils, offering tailored cannabinoid formulations for patient care.
Paragon 28's Shares Rise After Launch of Phantom Fibula Nail System
by Zacks Equity Research
FNA unveils Phantom Fibula Nail System, a less invasive, next-gen solution for ankle fractures, offering enhanced precision, stability and better patient outcomes.
Microbot Medical Stock Rises After Completing ACCESS-PVI Trial
by Zacks Equity Research
MBOT announces the successful completion of its ACCESS-PVI clinical trial for the LIBERTY Endovascular Robotic Surgical System, paving the way for FDA submission.
AtriCure's Stock Rises After Launch of cryoSPHERE MAX Device
by Zacks Equity Research
ATRC's cryoSPHERE MAX probe cuts freeze times by 50%, advancing Cryo Nerve Block therapy to improve post-op pain relief and reduce opioid dependency risks.
ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Zimmer Biomet's third-quarter results are likely to reflect the strength in its three business segments, namely Hips, Knees and S.ET.
IDXX Gears Up for Q3 Earnings: What to Expect From the Stock?
by Zacks Equity Research
IDEXX Laboratories' third-quarter 2024 performance is expected to have benefited from a strong execution against strategic priorities.
Will FARAPULSE Line Aid Boston Scientific's Q3 Earnings?
by Zacks Equity Research
BSX is expected to have registered strong growth in the Asia Pacific, which is led by strength in China and Japan.
GE HealthCare's Shares Rise After the Launch of Versana Premier
by Zacks Equity Research
GEHC launches Versana Premier, an AI-powered ultrasound system with advanced features designed for efficient, high-quality diagnostics across multiple specialties.
ALGN Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Align Technology's third-quarter results are likely to reflect the strength in its Clear Aligner and Systems & Services businesses.
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
by Zacks Equity Research
PACB partners with NCCS to enhance cancer research using the Onso short-read platform and Revio long-read sequencing, advancing precision oncology in Singapore and Asia.
Edwards Lifesciences to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
EW is likely to have witnessed continued growth in TAVR procedures across the United States and worldwide in the third quarter.
Abbott's Q3 Earnings Release Coming Up, EPD Business in Focus
by Zacks Equity Research
ABT's Neuromodulation growth is expected to have been driven by strong demand in international markets for the Eterna rechargeable spinal cord stimulation device.
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
by Zacks Equity Research
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
Labcorp's Q3 Earnings Looms: Here's What to Expect From the Stock
by Zacks Equity Research
LH is expected to perform strongly in both of its segments and will also likely advance in its strategic priorities.